Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Israel-based biopharmaceutical firm MediWound has signed an agreement granting BexPharm Korea exclusive rights to market and distribute NexoBrid in South Korea to treat severe burns upon receipt of regulatory approval.
Subscribe to our email newsletter
Around 10,000 patients with severe burns are hospitalized every year in South Korea and primarily are treated at about 10 burn centers.
The easy-to-use, topically-applied pharmaceutical product ‘NexoBrid’ removes dead or damaged tissue, known as eschar, in about four hours without harming the surrounding healthy tissue.
The new treatment for severe burns has received marketing authorization from the European Medicines Agency (EMA) for the removal of eschar in adults with deep partial and full-thickness thermal burns, and was commercially launched in Europe in December 2013
Sales of the product in South Korea will start after receipt of local regulatory approval, which will be filed with the South Korean authorities by BexPharm and is expected to be granted within a year or possibly longer.
Under the distribution agreement, in addition to revenues from the sales of NexoBrid, MediWound is also eligible to receive a consideration for the exclusive distribution right in the amounts set forth in the agreement, upon the consummation of certain milestones.
Apart from this agreement in South Korea, MediWound has recently executed exclusive distribution agreements for NexoBrid to treat severe burns in Russia with Genfa Medica and in Argentina with Tuteur S.A.C.I.F.I.A.
MediWound president and chief executive officer Gal Cohen said, "We believe this association will benefit MediWound as BexPharm Korea’s sales teams will focus on NexoBrid and provide close support to the specialists entrusted with the care of South Korea’s burn patients."